LIPO insider transaction filings
LIPELLA PHARMACEUTICALS INC. — 17 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-04-07. Screen LIPO transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for LIPO between 2026-06-25 and 2026-09-23. The table below lists the most recent filings on record.
Recent Form 4 filings — LIPELLA PHARMACEUTICALS INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-04-07 | 4 | Kaufman Jonathan H — See remarks below., Director, 10% owner | Other (J): 536,959 (derivative) @ $0 · Other (J): 125,833 (derivative) @ $0 · Other (J): 28,924 (derivative) @ $0 · Other (J): 4,060 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | Kaufman Jonathan H — See remarks below., Director, 10% owner | Other (J): 10,326 (derivative) @ $0 · Other (J): 4,060 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Kaufman Jonathan H — See remarks below., Director, 10% owner | Other (J): 84,700 (derivative) @ $0 · Other (J): 28,924 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Kaufman Jonathan H — See remarks below., Director, 10% owner | Other (J): 441,933 (derivative) @ $0 · Other (J): 125,833 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Kaufman Jonathan H — See remarks below., Director, 10% owner | Other (J): 303,041 (derivative) @ $0 · Other (J): 85,421 (derivative) @ $0 · Other (J): 11,795 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Kaufman Jonathan H — See remarks below., Director, 10% owner | Other (J): 42,933 (derivative) @ $0 · Other (J): 11,795 (derivative) @ $0 | EDGAR |
| 2024-05-15 | 4 | Kaufman Jonathan H — See remarks below., Director, 10% owner | Purchase (P): 10,000 @ $0.76 | EDGAR |
| 2024-03-19 | 4 | Yoshimura Naoki — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Pruchnic Ryan — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Chancellor Michael B — Chief Medical Officer, Director, 10% owner | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Birder Lori — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Kaufman Jonathan H — See remarks below., Director, 10% owner | Purchase (P): 30,000 @ $0.79 · Purchase (P): 25,000 @ $0.87 · Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Johnston Douglas — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Cohen Daniel R — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Kim Byong — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | Kaufman Jonathan H — See remarks below., Director, 10% owner | Grant/award (A): 144,906 @ $0.69 | EDGAR |
| 2024-03-15 | 4 | Chancellor Michael B — Chief Medical Officer, Director, 10% owner | Grant/award (A): 144,906 @ $0.69 | EDGAR |
Recent 8-K events — LIPELLA PHARMACEUTICALS INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-15 | 8-K | 1.03 — Bankruptcy or Receivership 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 1.03 — Bankruptcy or Receivership | EDGAR |
| 2026-02-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-10-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-10-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-09-18 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-25 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-20 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-16 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-05-16 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LIPO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →